InVentiv launches compliance/adherence business

Share this article:

InVentiv Health is launching a business aimed at improving patient compliance and adherence.
InVentiv Patient Outcomes, the firm's fourth business unit, will be led by Ed Mitzen, formerly of InVentiv companies CHS and Palio, who becomes president of the group.

The unit includes: The Therapeutics Institute, a corps of 300 nurse educators available to assist healthcare professionals in designing in-office patient education; Adheris, which offers pharmacy-based compliance and adherence programs; The Franklin Group, which offers reimbursement case management and patient assistance programs for patients who need financial support; and AWAC, which offers disease management support to third-party payors and physicians.

InVentiv acquired AWAC in June. Founder and CEO Dr. Rick Richards will stay on in that role, reporting to InVentiv COO Terrell Herring.

“Across InVentiv Health, most of the services we provide occur before the physician writes the prescription,” said Mitzen. “InVentiv Patient Outcomes is distinct because our focus is on what happens after the prescription is written. We see a significant opportunity to partner with healthcare providers, pharmaceutical companies, pharmacists and payors to help patients get the most from their therapy and ultimately achieve better health.”

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...